TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-13.2%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.35B
AUM Growth
+$2.35B
(-15%)
Cap. Flow
+$45.2M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
26
Reduced
10
Closed
4
Top Buys
| 1 |
Medtronic
MDT
|
$32.5M |
| 2 |
Eli Lilly
LLY
|
$23.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$23.4M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$15.2M |
| 5 |
WELL.PRI
Welltower Inc.
WELL.PRI
|
$12.4M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$61.2M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$35.4M |
| 3 |
Illumina
ILMN
|
$13.9M |
| 4 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
$12.5M |
| 5 |
ALR
Alere Inc
ALR
|
$11.6M |
Sector Composition
| 1 | Healthcare | 87.12% |
| 2 | Real Estate | 4.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Galapagos
GLPG
$2.06B
| $836K | 0.04% |
20,000
| – | – |
|
|
RVNC
127
DELISTED
Revance Therapeutics, Inc.
RVNC
| $786K | 0.03% |
+45,000
| New | +$786K |
|
|
BLCM
128
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $561K | 0.02% |
60,000
| – | – |
|
|
GNMK
129
DELISTED
GenMark Diagnostics, Inc
GNMK
| $492K | 0.02% |
93,349
| – | – |
|
130
Celldex Therapeutics
CLDX
$1.57B
| $400K | 0.02% |
105,800
| – | – |
|
131
Xencor
XNCR
$594M
| $268K | 0.01% |
20,000
| – | – |
|
132
The RMR Group
RMR
$279M
| $186K | 0.01% |
7,441
| – | – |
|
133
Larimar Therapeutics
LRMR
$337M
| $89K | ﹤0.01% |
13,307
| – | – |
|
134
AbbVie
ABBV
$374B
| $9K | ﹤0.01% |
156
| – | – |
|
|
BXLT
135
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| – | – |
-319,600
| Closed | -$12.5M |
|
|
ALR
136
DELISTED
Alere Inc
ALR
| – | – |
-297,901
| Closed | -$11.6M |
|
|
WCG
137
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-88,652
| Closed | -$6.93M |
|
|
GWPH
138
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-30,000
| Closed | -$2.08M |
|